0.1114
Schlusskurs vom Vortag:
$0.1115
Offen:
$0.1127
24-Stunden-Volumen:
530.09K
Relative Volume:
0.42
Marktkapitalisierung:
$6.92M
Einnahmen:
$1.47M
Nettoeinkommen (Verlust:
$-97.61M
KGV:
-0.0748
EPS:
-1.49
Netto-Cashflow:
$-80.90M
1W Leistung:
+6.10%
1M Leistung:
-4.46%
6M Leistung:
-56.97%
1J Leistung:
-97.59%
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Firmenname
Lyra Therapeutics Inc
Sektor
Branche
Telefon
617-373-4600
Adresse
480 ARSENAL WAY, WATERTOWN, MA
Vergleichen Sie LYRA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LYRA
Lyra Therapeutics Inc
|
0.1114 | 6.92M | 1.47M | -97.61M | -80.90M | -1.49 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.54 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
608.10 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.41 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.71 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.50 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-05-07 | Herabstufung | BofA Securities | Buy → Underperform |
2024-05-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-05-07 | Herabstufung | Jefferies | Buy → Hold |
2024-05-06 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-10-06 | Fortgesetzt | BTIG Research | Buy |
2023-08-31 | Eingeleitet | H.C. Wainwright | Buy |
2022-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-05-26 | Eingeleitet | BTIG Research | Buy |
2020-05-26 | Eingeleitet | BofA/Merrill | Buy |
2020-05-26 | Eingeleitet | Jefferies | Buy |
2020-05-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten
Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - Sete News
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements - openPR.com
Keeping an Eye on Lyra Therapeutics Inc (LYRA) After Insider Trading Activity - knoxdaily.com
Lyra Therapeutics Inc (LYRA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
What was Lyra Therapeutics Inc (LYRA)’s performance in the last session? - uspostnews.com
Recent Insider Activity Could Benefit Schrodinger Inc (SDGR) - knoxdaily.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
iCoreConnect Inc [ICCT] Shares Fall Approximately -87.86% Over the Year - knoxdaily.com
Lyra Therapeutics Inc [LYRA] Shares Rise 7.02 % on Thursday - knoxdaily.com
QBTS Stock Sees Surge of Approximately 14.13% in Last Five Days - knoxdaily.com
Deckers Outdoor Corp [DECK] Records 200-Day SMA of $160.33 - knoxdaily.com
Shopify Inc [SHOP] Records 50-Day SMA of $99.94 - knoxdaily.com
Analysts Say Lyra Therapeutics Inc (NASDAQ:LYRA) Can Really Get To 0.5 In 12 Months - Marketing Sentinel
An Analysis of Lyra Therapeutics Inc (LYRA)’s Potential Price Growth - knoxdaily.com
Take off with Lyra Therapeutics Inc (LYRA): Get ready for trading - Sete News
Is Lyra Therapeutics Inc (LYRA) worth investing in despite its undervalued state? - uspostnews.com
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World
Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia
Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com
TCBI Stock Sees Decline of Approximately -2.19% in Last Five Days - knoxdaily.com
Mateon Therapeutics (OTCMKTS:MATN) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia
PTCT Stock Sees Decline of Approximately -2.93% in Last Five Days - knoxdaily.com
Lyra Therapeutics Inc (LYRA) deserves deeper analysis - uspostnews.com
A Closer Look at Lyra Therapeutics Inc (LYRA) Stock Gains - investchronicle.com
Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia
Lyra Therapeutics stock plunges to 52-week low of $0.16 - Investing.com India
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $4.50 - Defense World
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Earns “Neutral” Rating from HC Wainwright - Defense World
Lyra Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FDA Green Light: Lyra's Nasal Polyp Treatment Advances as 52-Week Data Shows Promise - StockTitan
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c) - TipRanks
Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Thursday - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
Chronic Rhinosinusitis Pipeline 2024: FDA Updates, Therapy - openPR.com
Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):